Clear Harbor Asset Management LLC Boosts Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Clear Harbor Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 23.8% in Q2, owning 8,419 shares worth approximately $4.42 million.
• A variety of institutional investors have also adjusted their positions in Regeneron, with GAMMA Investing LLC significantly increasing its stake by 89,825.0%, now holding 815,620 shares valued at $517.29 million.
• Wall Street analysts overall maintain a consensus rating of Moderate Buy for Regeneron, with a consensus target price of $817.67, despite price target adjustments from other firms.

Clear Harbor Asset Management LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 23.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,419 shares of the biopharmaceutical company's stock after acquiring an additional 1,616 shares during the quarter. Clear Harbor Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $4,420,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in REGN. Marietta Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after buying an additional 2,501 shares during the period. Sepio Capital LP increased its stake in Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock worth $2,150,000 after acquiring an additional 842 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after buying an additional 12,793 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target on the stock. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Finally, Sanford C. Bernstein lifted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Trading Down 1.1%

Regeneron Pharmaceuticals stock opened at $591.99 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The business's 50-day simple moving average is $567.77 and its 200-day simple moving average is $574.26. The firm has a market capitalization of $62.75 billion, a PE ratio of 14.92, a PEG ratio of 1.98 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the company posted $11.56 earnings per share. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.